Fleury SA operates within the Medical laboratories sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Fleury SA with three other
pharmaceutical manufacturers in Latin America:
Genomma Lab Internacional Sab De Cv
sales of 13.87 billion Mexican Pesos [US$688.65 million]
of which 100%
Instituto Hermes Pardini SA
(1.49 billion Brazilian Reals [US$280.56 million]
of which 100%
was auxiliary diagnostic support services), and
(4.09 billion Brazilian Reals [US$767.85 million]
Sales were up sharply during the second
quarter of 2021 versus the previous year's second quarter.
During the second
quarter of 2021, sales at Fleury SA totalled
932.07 million Brazilian Reals.
an increase of 104.9%
from the 454.94 million Brazilian Reals in sales at the company during the second quarter of 2020.
This was the biggest same quarter rise in sales at Fleury SA in the previous 35 quarters.
During the first two
quarters of 2021, sales totalled 1.83 billion Brazilian Reals, which is
than through the first two quarters of 2020.
There appears to be at least some degree of seasonality in the sales at Fleury SA: during 8 of the previous 9
years, sales were highest during the third quarter.
The exception to this was during 2020, when the
fourth quarter was the best quarter, accounting for
31% of sales (during that same year, the
third quarter accounted for 29% of sales).
During the year ended December of 2020, sales at
Fleury SA were 2.97 billion Brazilian Reals (US$558.04 million).
increase of 2.3%
versus 2019, when the company's sales were 2.91 billion Brazilian Reals.
This was the fifth consecutive year of sales increases at Fleury SA
(and since 2015, sales have increased a total of 57%).
Sales of Integrated Medicine saw an increase
that was more than double the company's growth rate: sales were up
15.3% in 2020, from
467.62 million Brazilian Reals to 538.93 million Brazilian Reals.
Not all segments of Fleury SA experienced an increase in sales in 2020:
sales of Diagnostic Medicine fell 0.2% to 2.43 billion Brazilian Reals.